Mavyret Alternatives Compared
| Mavyret | Epclusa | Harvoni |
|
|---|
| Mavyret (glecaprevir / pibrentasvir) | Epclusa (sofosbuvir / velpatasvir) | Harvoni (ledipasvir / sofosbuvir) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Mavyret is an antiviral combination agent that is approved to treat all six genotypes (1-6) of hepatitis C virus (HCV) in adults and children aged 12 years of age and older. It is one of the most... View more |
Prescription only
Epclusa is a combination tablet containing velpatasvir and sofosbuvir. It may be used to treat all six genotypes of the hepatitis C virus in adults and children over the age of three. It is usually... View more |
Prescription only
Harvoni is a combination tablet containing ledipasvir and sofosbuvir. It may be used to treat certain genotypes of the hepatitis C virus in adults and children over the age of three. It is usually... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Mavyret (glecaprevir / pibrentasvir) | More about Epclusa (sofosbuvir / velpatasvir) | More about Harvoni (ledipasvir / sofosbuvir) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
||||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Mavyret has an average rating of 8.4 out of 10 from a total of 408 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 8% reported a negative effect. |
Epclusa has an average rating of 7.7 out of 10 from a total of 367 ratings on Drugs.com. 66% of reviewers reported a positive effect, while 13% reported a negative effect. |
Harvoni has an average rating of 8.6 out of 10 from a total of 397 ratings on Drugs.com. 81% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Mavyret side effects in more detail. |
See also: Epclusa side effects in more detail. |
See also: Harvoni side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mavyret prices |
View all Epclusa prices and generic prices |
View all Harvoni prices and generic prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
13 hours |
27 hours |
47 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 180 drugs are known to interact with Mavyret:
|
A total of 180 drugs are known to interact with Epclusa:
|
A total of 171 drugs are known to interact with Harvoni:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 03, 2017 |
June 28, 2016 |
October 10, 2014 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.